Can J Anaesth 70(8):13971400
As with other medications that affect appetite-regulating hormones, ongoing clinical trials continue to monitor long-term safety and identify any rare risks
doi:10.1016/j.jconrel.2023.04.027
There are reports of acute kidney injury in at-risk patients
Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
IV Therapy At Elle Aesthetic Arts & Plastic Surgery, our focus goes beyond cosmetic treatments